Repeated Exposure to Eltrombopag in Adults With Idiopathic Thrombocytopenic Purpura (REPEAT)
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
This open-label, repeat dosing study, TRA108057, will evaluate the efficacy, safety and
tolerability of eltrombopag, when administered in a repeat, cyclic dosing schedule. The study
will describe the effect of repeated (3 cycles), intermittent dosing of eltrombopag on the
pharmacodynamics and durability of eltrombopag response as measured by the peripheral
platelet counts.
For more information or to see if you qualify, please visit: http://www.itpstudy.com/gov